Based on our results, we identified m6A writer METTL16 as a unique candidate that is differentially expressed among tissue samples that carry the most frequently mutated genes that characterize PDA and has potential as a favorable prognostic biomarker. The gene discussed is METTL16; the disease is Patent ductus arteriosus.